Biora Therapeutics Inc. Common Stock BIOR · Stock Open Biora Therapeutics Inc. Common Stock in new tab
Biora Therapeutics Inc. Common Stock Analysis (BIOR)
Is Biora Therapeutics Inc. Common Stock a good investment? Biora Therapeutics Inc. Common Stock (BIOR) is currently trading at 0.2200 USD. Market analysts have a consensus price target of 34.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.61. This relatively low multiple may signal that Biora Therapeutics Inc. Common Stock is undervalued compared to historical market norms.
Investor FAQ
Does Biora Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Biora Therapeutics Inc. Common Stock?
Biora Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 3, 2023 | 1:25 |
| Oct. 18, 2024 | 1:10 |
Community Discussion